Assessment of Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease

Gigante, Antonietta; Perrotta, Adolfo; Tinti, Francesca; Assanto, Eleonora; Muscaritoli, Maurizio; Lai, Silvia; Cianci, Rosario

doi:10.3390/app13127175

Cited by 3 publications

(2 citation statements)

References 57 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular abnormalities related to ADPKD can vary among individuals and may not be present in all patients. Regular cardiovascular evaluations and monitoring are recommended to assess and manage these potential complications in ADPKD patients [124,125].…”

Section: Heartmentioning

confidence: 99%

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement

Righini,

Mancini,

Busutti

et al. 2024

IJMS

View full text Add to dashboard Cite

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder, but kidneys are not the only organs involved in this systemic disorder. Individuals with the condition may display additional manifestations beyond the renal system, involving the liver, pancreas, and brain in the context of cystic manifestations, while involving the vascular system, gastrointestinal tract, bones, and cardiac valves in the context of non-cystic manifestations. Despite kidney involvement remaining the main feature of the disease, thanks to longer survival, early diagnosis, and better management of kidney-related problems, a new wave of complications must be faced by clinicians who treated patients with ADPKD. Involvement of the liver represents the most prevalent extrarenal manifestation and has growing importance in the symptom burden and quality of life. Vascular abnormalities are a key factor for patients’ life expectancy and there is still debate whether to screen or not to screen all patients. Arterial hypertension is often the earliest onset symptom among ADPKD patients, leading to frequent cardiovascular complications. Although cardiac valvular abnormalities are a frequent complication, they rarely lead to relevant problems in the clinical history of polycystic patients. One of the newest relevant aspects concerns bone disorders that can exert a considerable influence on the clinical course of these patients. This review aims to provide the “state of the art” among the extrarenal manifestation of ADPKD.

show abstract

Section: Heartmentioning

confidence: 99%

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement

Righini,

Mancini,

Busutti

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Cardiovascular disease (CVD) is the major cause of mortality in ADPKD cases and contributes to a significant disease burden [14][15][16][17]. Patients with ADPKD experience CVD events with greater severity and have an increased risk of CVD-related death as compared to the general population, with 33% of those mortalities mainly due to ischemic heart disease or congestive heart failure [18].…”

Section: Introductionmentioning

confidence: 99%

Short-Term Dapagliflozin Administration in Autosomal Dominant Polycystic Kidney Disease—A Retrospective Single-Arm Case Series Study

Morioka,

Nakatani,

Uedono

et al. 2023

JCM

View full text Add to dashboard Cite

Treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors may have pleiotropic and beneficial effects in terms of ameliorating of risk factors for the progression of autosomal dominant polycystic kidney disease (ADPKD). However, there is insufficient evidence regarding the use of these drugs in patients with ADPKD, as they were excluded from several clinical trials conducted to explore kidney protection provided by SGLT2 inhibitors. This retrospective single-arm case series study was performed to investigate the effects of dapagliflozin, a selective SGLT2 inhibitor administered at 10 mg/day, on changes in height-adjusted kidney volume (htTKV) and estimated glomerular filtration rate (eGFR) in ADPKD patients. During a period of 102 ± 20 days (range 70–156 days), eGFR was decreased from 47.9 (39.7–56.9) to 40.8 (33.7–44.5) mL/min/1.73 m2 (p < 0.001), while htTKV was increased from 599 (423–707) to 617 (446–827) mL/m (p = 0.002) (n = 20). The annual increase in htTKV rate was significantly promoted, and urinary phosphate change was found to be correlated with the change in htTKV (rs = 0.575, p = 0.020). In the examined patients, eGFR was decreased and htTKV increased during short-term administration of dapagliflozin. To confirm the possibility of the effects of dapagliflozin on ADPKD, additional interventional studies are required.

show abstract

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement

Righini,

Mancini,

Busutti

et al. 2024

Preprint

View full text Add to dashboard Cite

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder but kidneys are not the only organs involved in this systemic disorder. Individuals with the condition may display additional manifestations beyond the renal system, involving liver, pancreas and brain in the con-text of cystic manifestations, while vascular system, gastrointestinal tract, bones, and cardiac valves in the context of non-cystic manifestations. Despite kidney involvement remain the main feature of the disease, thanks to new generation therapies, early diagnosis and better management of kidney related problems, a new wave of complications must be faced from clinicians who treated polycystic patients. Involvement of the liver represents the most prevalent extrarenal manifestation and grows importance in symptom burden and quality of life. Vascular abnormalities are a key factor for patients’ life expectancy and there’s still de-bate whether to screen or not to screen all patients. Arterial hypertension is often the earliest onset among polycystic patients leading to frequent cardiovascular complications. Although cardiac valvular abnormali-ties is a frequent complication, it rarely leads to relevant problems in the clinical history of polycystic pa-tients. One of the new relevant aspects concern bone disorders, that can exert a considerable influence on the clinical course of these patients. This review aims to provide the “state of art” among extrarenal mani-festation of ADPKD.

show abstract

Assessment of Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease

Cited by 3 publications

References 57 publications

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement

Short-Term Dapagliflozin Administration in Autosomal Dominant Polycystic Kidney Disease—A Retrospective Single-Arm Case Series Study

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement

Contact Info

Product

Resources

About